(BIDZ, OSIR, CRWE, MRCY) PennyOmega.com Stocks to Watch for Friday May 18, 2012

BIDZ, BIDZ.com, Inc.
** BIDZ reported that it has entered into a definitive merger agreement with Glendon Group, Inc. to be acquired for $0.78 per share in cash.
This per share price represents a premium of 59.2% over BIDZ’s closing price of $0.49 per share, on May 16, 2012, the last trading day prior to the execution of the merger agreement, and a premium of 37.7% over BIDZ’s volume-weighted average of the closing prices over the 30 consecutive trading days including and immediately preceding May 16, 2012.
BIDZ is a leading online retailer of jewelry. BIDZ offers its products through a live auction format as well as a fixed price online retail store, Buyz.com. BIDZ also operates Modnique.com, a division of Bidz.com, a flash sale shopping website, offering authentic premium brand name merchandise. Modnique offers its members exclusive access to 24-72 hour sales events on designer apparel, accessories, shoes, and housewares and much more at price points up to 85% below traditional retail prices.
More about BIDZ at www.bidz.com
***************
OSIR, Osiris Therapeutics, Inc.
** OSIR reported that it has received market authorization from Health Canada to market its stem cell therapy Prochymal(R) (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.
The historic decision marks the world’s first regulatory approval of a manufactured stem cell product and the first therapy approved for GvHD — a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis.
Prochymal was authorized under Health Canada’s Notice of Compliance with conditions (NOC/c) pathway, which provides access to therapeutic products that address unmet medical conditions and which have demonstrated a favorable risk/benefit profile in clinical trials. Under the NOC/c pathway, the sponsor must agree to carry out confirmatory clinical testing.
Health Canada’s authorization was made following the recommendation of an independent expert advisory panel, commissioned to evaluate Prochymal’s safety and efficacy. In Canada, Prochymal is now authorized for the management of acute GvHD in children who fail to respond to steroids.
Prochymal is currently available in several countries, including the United States, under an Expanded Access Program (EAP). Prochymal will be commercially available in Canada later this year.
In addition to the extensive intellectual property protection OSIR has around Prochymal, which includes 48 issued patents, Health Canada’s decision will also provide Prochymal with regulatory exclusivity within the territory. Canada affords eight years of exclusivity to Innovative Drugs such as Prochymal, and an additional six-month extension is available since it addresses a pediatric population.
GvHD represents a major unmet medical need with no approved treatment until Prochymal. GvHD is the leading cause of transplant related mortality, in which immune cells contained within the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. Severe GvHD can cause blistering of the skin, intestinal hemorrhage and liver failure. Severe GvHD is extremely painful and fatal in up to 80 percent of cases. Currently, steroids are used as first-line therapy with a success rate of only 30-50 percent. When steroids fail, treatment options are limited to immunosuppressive agents used off-label with little benefit and significant toxicities.
Prochymal is the world’s first approved drug which has a stem cell as its active ingredient. Developed by OSIR, Prochymal is an intravenous formulation of mesenchymal stem cells (MSCs), which are derived from the bone marrow of healthy adult donors between the ages of 18 and 30 years.
OSIR is the leading stem cell company, having developed the world’s first approved stem cell drug, Prochymal. OSIR is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic areas and wound healing areas.
More about OSIR at www.Osiris.com
***************
MRCY, Mercury Computer Systems, Inc.
** MRCY reported that it has received a contract from a leading defense prime contractor to provide an advanced solid state data recorder for the aggregation and storage of sensor data from airborne ISR applications.
MRCY’s solution combines the very high density capacity Digital Storage Unit (DSU) with a controller function built to the 3U OpenVPX standard. The DSU uses an array of commercially available Solid State Disk (SSD) components configured within a compact, rugged, deployable enclosure, while the controller supports flexible protocol conversions as part of the data recording process.
MRCY is a best-of-breed provider of open, commercially developed, application-ready, multi-INT subsystems for defense prime contractors.
More about MRCY at www.mc.com
*****************
CRWE, Crown Equity Holdings Inc., CRWE.OB
Online video enables a totally new level of valuable communication among businesses – not only inside corporations themselves, but with respect to their client base.
CRWE recenly launched CRWE Tube, www.crwetube.com, a video sharing site that allows billions of people around the world to upload, watch and share original videos.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWE‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
More about CRWE at www.crownequityholdings.com.
**********************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
Tags: BIDZ, BIDZ.com, Crown Equity Holdings, CRWE, Mercury Computer, MRCY, Nasdaq:BIDZ, Nasdaq:MRCY, Nasdaq:OSIR, OSIR, Osiris Therapeutics, otc:crwe











GTAT, GT Advanced Technologies Inc.
EGHT, 8×8 Inc.
CRWE’s division CRWE AD-Services (
CHMT, Chemtura Corporation

USHS, U.S. Home Systems Inc.
